summarized
stringlengths
41
385
Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways kill cancer cells . Combining monoclonal antibody therapy chemotherapy may kill cancer
MP470 may stop growth cancer cells blocking enzymes needed to grow . MP470 may stop growth cancer cells blocking enzymes needed to grow .
Interleukin-12 may kill tumor cells stopping blood flow . White blood cells stimulating person's white blood cells kill cancer cells .
Gossypol given together paclitaxel carboplatin given together paclitaxel carboplatin . Gossypol given together paclitaxel carboplatin treating patients solid tumors metastatic cannot removed surgery .
This study designed long-term follow-up study participants receive genetically modified autologous CAR-T cells .
Genetic testing specific enzyme may help doctors determine whether side effects response chemotherapy related person's genetic makeup . Genetic testing specific enzyme may help doctors determine whether side effects response chemotherapy related person's genetic makeup .
Monoclonal antibodies, rituximab, block cancer growth different ways . Some find cancer cells help kill carry cancer-killing substances . Others interfere ability cancer cells grow spread .
Phase I trial studying side effects of vorinostat given together decitabine .
PXD101 bortezomib may stop growth cancer cells blocking enzymes needed cell growth . PXD101 may also cause cancer cells look like normal cells, grow spread slowly .
Bortezomib may stop growth cancer cells blocking enzymes necessary growth . Bortezomib may increase effectiveness flavopiridol making cancer cells sensitive drug .
Phase I trial studying side effects of 17-DMAG . Drug is used to treat patients with metastatic unresectable solid tumors lymphomas .
The purpose study determine rate response drugs bortezomib (Velcade) vorinostat (Zolinza) The purpose study determine rate response drugs bortezomib (Velcade) vorinostat
RO4929097 given together capecitabine given together capecitabine treating patients refractory solid tumors . RO4929097 may stop growth tumor cells blocking enzymes needed cell growth .
Radiolabeled drugs yttrium Y 90 SMT 487 locate tumor cells and deliver tumor-killing substances without harming normal cells . yttrium Y 90 SMT 487 is being tested in Phase I trial study .
Antiemetic drugs, aprepitant, ondansetron, dexamethasone, may help lessen prevent nausea vomiting patients undergoing stem cell transplant .
Drugs used chemotherapy, FAU, work different ways stop growth cancer cells . Drugs used chemotherapy, FAU, work different ways stop growth cancer cells . FAU is either killing cells or stopping dividing cells .
Copanlisib may stop growth tumor cells blocking enzymes needed cell growth . Copanlisib given together nivolumab works treating patients Richter's transformation transformed non-Hodgkin lymphoma .
10-propargyl-10-deazaaminopterin was used in Phase II trial study . 10-propargyl-10-deazaaminopterin was used to treat patients with non-Hodgkin's
A significant number patients non-Hodgkin lymphoma (NHL) cured available treatments eventually relapse . Those patients might able tolerate bone marrow toxicity, limiting treatment options . Preclinical vitro studies demonstrated synergism venetoclax cop
Phase II trial studying effectiveness donor peripheral blood stem cell transplant treating patients hematologic cancer .
Phase I trial studying side effects of 17-N-allylamino-17-demethoxygeldanamycin . 17-N-allylamino-17-demethoxygeldanamycin treating patients advanced
Ibrutinib may stop growth cancer cells blocking enzymes needed to grow . This phase I trial studies side effects best dose selinexor given together ibrutinib .
Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give higher doses of drugs kill cancer cells . Monoclonal antibodies locate cancer cells either kill deliver cancer-
Radiolabeled monoclonal antibodies locate cancer cells deliver cancer-killing substances without harming normal cells . Phase I/II trial study effectiveness radiolabeled monoclonal antibody therapy treating patients lymphoma leukemia responded previous chemotherapy
Phase II trial studying well topotecan hydrochloride works treating children meningeal cancer . Children's meningeal cancer responded previous treatment .
The purpose study collect long-term safety efficacy data . Participants treated ibrutinib provide ongoing access to ibrutinib participants currently enrolled ibrutinib studies completed according parent protocol . Participants currently enrolled ibrut
Bortezomib may stop growth cancer cells blocking enzymes needed to grow . Bortezomib given together gemcitabine may kill cancer cells .
Phase II trial study effectiveness of combination chemotherapy . Combining one drug may kill tumor cells . Patients with Hodgkin's disease non-Hodgkin's lymphoma responded previous treatment .
Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining one drug may kill cancer cells .
Phase I/II trial studies whether stopping cyclosporine mycophenolate mofetil better reducing risk of graft-versus-host disease (GVHD) previous approach mycophenolate mofetil stopped cycl
Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, ethanol may help prevent blockages infections forming patients central venous access catheters .
Ibrutinib may stop growth cancer cells blocking enzymes needed to stop cell growth . It yet known whether safe patients HIV infection receive ibrutinib also taking anti-HIV drugs .
Keratinocyte growth factor may prevent symptoms mucositis patients receiving radiation therapy chemotherapy . Keratinocyte growth factor may prevent symptoms mucositis patients receiving radiation therapy chemotherapy.
Combining chemotherapy bone marrow transplantation may allow doctor give higher doses chemotherapy drugs kill cancer cells . Phase II trial study effectiveness combination chemotherapy consisting busulfan cyclophosphamide followed bone marrow transplantation treating patients acute chronic leukemia myelod
This expanded access protocol conducted sites qualified approved treat subjects lisocabtagene maraleucel . Sometimes lisocabtagene maraleucel manufactured drug pass testing results called lisocabtagene maraleu
Phase II trial study effectiveness of combination chemotherapy treating patients AIDS-related lymphoma . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining one drug may kill cancer cells .
Phase I/II trial studies side effects of best dose anti-cluster differentiation (CD)20 radioimmunotherapy (RIT) RIT attaches radioactive material drug designed target CD20, brings radioactive material cancer cells kill cells .
Phase I trial study effectiveness combining topotecan, fluorouracil, leucovorin . Combining one drug may kill tumor cells .
PDX101 may stop growth cancer cells blocking enzymes needed cell growth blocking blood flow cancer . PDX101 may stop growth cancer cells blocking enzymes needed needed cell growth blocking blood flow cancer .
GS-0189 (formerly FSI-189) monotherapy combination rituximab participants relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) participants relapsed/
Phase I trial study combining ZD0473 doxorubicin with ZD0473 doxorubicin . Phase I trial study effectiveness combining ZD0473 doxorubicin treating patients advanced solid
Monoclonal antibodies, rituximab, block cancer growth different ways . Some find cancer cells kill carry cancer-killing substances them . Others interfere ability cancer cells grow spread . Radiation therapy uses high-energy x-rays
Phase I trial studying side effects of azacitidine plus phenylbutyrate . Trials include patients with advanced metastatic solid tumors who responded to previous treatment .
Combining one drug giving drugs different ways may kill cancer cells . Radiation therapy uses high-energy x-rays damage cancer cells . It yet known combination chemotherapy regimen followed radiation therapy effective treating aggressive non-Hodgkin's lymphoma
Monoclonal antibodies, rituximab, block cancer growth different ways . Some find cancer cells kill carry cancer-killing substances . Others interfere ability cancer cells grow spread .
Motexafin gadolinium may increase effectiveness doxorubicin making tumor cells sensitive drug . Motexafin gadolinium may increase effectiveness doxorubicin making tumor cells sensitive drug .
NX-5948 patients advanced B-cell malignancies are first in a human dose escalation cohort expansion . The study is designed to evaluate safety preliminary efficacy for advanced B-cell malignancies .
Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die .
This phase 1, open-label, dose-escalation, multicenter study evaluate safety tolerability of SGN-CD19A patients . Patients relapsed refractory B-lineage non-Hodgkin lymphoma
The trial open-label, multi-center safety preliminary efficacy trial epcoritamab Japan is open-label, multi-center safety preliminary efficacy trial . The purpose dose-escalation part trial determine maximum tolerated dose (MTD
The purpose study evaluated safety tolerability of BGB-11417 monotherapy . The purpose study evaluated safety tolerability of BGB-11417 monotherapy . The study evaluated BGB-11417 monotherapy selected B-cell mal
CPI-613 (6,8-bis[benzylthio]octanoic acid) given together bendamustine hydrochloride rituximab . Rituximab may find cancer cells help kill
Monoclonal antibodies, rituximab, block cancer growth different ways . Some block ability cancer cells grow spread . Others find cancer cells help kill carry cancer-killing substances .
Monoclonal antibodies rituximab locate cancer cells either kill deliver cancer-killing substances without harming normal cells . Drugs used chemotherapy use different ways stop cancer cells dividing stop growing die . Combining chemotherapy peripheral stem cell transplantation